In HCC, patients’ radiotherapy (RT) seems to increase sPD-L1 levels, resulting in a poorer short- and long-term efficacy, highlighting the possible therapeutic benefits of a combined strategy that includes RT and anti-PD-L1 immunotherapy [43]. This evidence concerns the gene SPDL1 and hepatocellular carcinoma.